# Locana

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/locana-2

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.locanabio.com
- Total disclosed funding: $160M
- Latest round: Series B (Dec 14, 2020)
- Investors on record: 10

## About

Locana, Inc. specializes in developing innovative genetic medicines by harnessing the power of gene editing technologies to address various diseases and improve patient outcomes.Founded in 2016, Locana, Inc. operates in San Diego, US, with a focus on gene editing solutions. The company was established by Gene Yeo, who has experience in biotechnology innovation. Locana has raised funding through three deals, most recently securing USD 100 mn in Series B funding on December 14, 2020, led by Vida Ventures with participation from notable investors including ARCH Venture Partners and UCB Ventures. The total amount raised to date is USD 100 mn, with a current company valuation of USD 280.31 mn.Locana's primary offerings include advanced gene editing technologies aimed at delivering effective genetic medicines. These innovative solutions address critical health challenges by providing precision therapies for various genetic disorders. The company's client base covers a broad spectrum of healthcare providers and research institutions focused on innovative treatment methods and patient care improvements.Locana generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and research institutions, leveraging its proprietary gene editing technologies. The firm's pricing model is designed to enable accessibility for various research and development projects, ensuring broad market engagement for its advanced therapeutic solutions.Looking ahead, Locana plans to expand its product portfolio with new gene therapy solutions targeting specific diseases, with anticipated launches in the next 12 to 18 months. The company aims to penetrate new markets in Europe and Asia, focusing on collaborations with local biotech firms by 2022. The recent Series B funding of USD 100 mn will support the development of these new therapies and market expansion efforts, enabling Locana to enhance its operational capabilities and accelerate its growth strategy.

## Funding rounds

- Series B, Dec 14, 2020, $100M — ARCH Venture Partners, Invus [DUP], GV, Temasek Holdings, Lightstone Ventures, RA Capital Management, Acuta Capital Partners, Vida Ventures, UCB Ventures, SVB Leerink
- Series A, May 22, 2019, $60M — ARCH Venture Partners, Temasek Holdings, GV, Lightstone Ventures, UCB Ventures

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Temasek Holdings — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A, Series B
- UCB Ventures (https://capitalatlas.ai/funds/ucb-ventures) — Series A, Series B
- Invus [DUP] — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Acuta Capital Partners (https://capitalatlas.ai/funds/acuta-capital-partners) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B
- SVB Leerink — Series B